Tamoxifen, tablets 20 mg 30 pcs

Cancer, Breast Cancer

• Breast cancer in menopausal women;
• breast cancer in men after castration;
• kidney cancer;
• melanoma (containing estrogen receptors);
• ovarian cancer;
• prostate cancer in resistance to other drugs.

.

Indications

Breast cancer in menopausal women;
breast cancer in men after castration;
kidney cancer;
melanoma (containing estrogen receptors);
ovarian cancer;
prostate cancer with resistance to other drugs.

Active ingredient

Tamoxifen

Composition

1 tablet contains:

Active substances:

tamoxifen citrate 30.4 mg, which is equivalent to the content of tamoxifen 20 mg.

Excipients:

corn starch,

lactose monohydrate,

povidone,

sodium starch glycolate,

magnesium stearate,

purified water.

Contraindications

Thrombophlebitis;
pregnancy;
hypersensitivity to tamoxifen.

Side Effects

From the digestive system: nausea, vomiting, increased activity of liver transaminases; in some cases – fatty liver infiltration, cholestasis, hepatitis.

From the side of the central nervous system: rarely – depression, dizziness, headache, retrobulbar neuritis.

From the organ of vision: rarely – retinopathy, keratopathy, cataract.

From the hematopoietic system: rarely – thrombocytopenia, leukopenia.

From the endocrine system: in women – endometrial hyperplasia, vaginal bleeding, hot flashes, weight gain; in men – impotence, decreased libido.

From the cardiovascular system: edema, thromboembolism, phlebitis.

Dermatological reactions: alopecia, rash, itching.

Other: pain in bones and lesions, increased body temperature.

Interaction

When used simultaneously with coumarin derivatives anticoagulants, the risk of increased anticoagulant action increases; with cytostatics – there may be an increased risk of thrombosis.

When used simultaneously with allopurinol, hepatotoxicity is possible; with aminoglutethimide – a decrease in the concentration of tamoxifen in plasma, apparently due to an increase in its metabolism.

In patients receiving tamoxifen, the neuromuscular blockade caused by atracurium may be prolonged.

With simultaneous use of bromocriptine, the dopaminergic effect of bromocriptine may be enhanced. In patients receiving tamoxifen, when using warfarin, there is a risk of developing a threatening clinical situation: prolongation of prothrombin time, hematuria, and hematoma are possible.

When used simultaneously with mitomycin, the risk of developing hemolytic-uremic syndrome increases.

There may be a decrease in the concentration of tamoxifen in the blood plasma, which is apparently due to the induction of the CYP3A4 isoenzyme under the influence of rifampicin.

Estrogens may reduce the therapeutic effect of tamoxifen.

Overdose

Acute overdose with tamoxifen has not been observed in humans.

Symptoms: It should be expected that an overdose may cause an increase in the above-described adverse reactions.

Treatment: There are no specific antidotes; treatment should be symptomatic.

Storage conditions

Store at 15–25 °C.

Shelf life

2 years.

Manufacturer

Ozon, Russia